- Home
- IIIV vs TRML Comparison
IIIV vs TRML Comparison
Compare IIIV & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- TRML
- Stock Information
- Founded
- IIIV 2012
- TRML 2021
- Country
- IIIV United States
- TRML United States
- Employees
- IIIV N/A
- TRML N/A
- Industry
- IIIV EDP Services
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- IIIV Technology
- TRML Health Care
- Exchange
- IIIV Nasdaq
- TRML Nasdaq
- Market Cap
- IIIV 570.8M
- TRML 509.8M
- IPO Year
- IIIV 2018
- TRML N/A
- Fundamental
- Price
- IIIV $27.71
- TRML $12.21
- Analyst Decision
- IIIV Buy
- TRML Strong Buy
- Analyst Count
- IIIV 7
- TRML 6
- Target Price
- IIIV $29.86
- TRML $54.00
- AVG Volume (30 Days)
- IIIV 256.0K
- TRML 338.2K
- Earning Date
- IIIV 02-06-2025
- TRML 03-18-2025
- Dividend Yield
- IIIV N/A
- TRML N/A
- EPS Growth
- IIIV 21740.15
- TRML N/A
- EPS
- IIIV 4.87
- TRML N/A
- Revenue
- IIIV $236,560,000.00
- TRML N/A
- Revenue This Year
- IIIV $12.59
- TRML N/A
- Revenue Next Year
- IIIV $8.24
- TRML N/A
- P/E Ratio
- IIIV $5.61
- TRML N/A
- Revenue Growth
- IIIV 20.85
- TRML N/A
- 52 Week Low
- IIIV $18.75
- TRML $12.12
- 52 Week High
- IIIV $29.80
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- IIIV 57.83
- TRML 25.27
- Support Level
- IIIV $27.96
- TRML $12.13
- Resistance Level
- IIIV $29.66
- TRML $14.58
- Average True Range (ATR)
- IIIV 1.19
- TRML 0.84
- MACD
- IIIV -0.00
- TRML -0.05
- Stochastic Oscillator
- IIIV 61.86
- TRML 1.79
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.